Cargando…

Can a Synbiotic Supplementation Contribute to Decreasing Anti-Tissue Transglutaminase Levels in Children with Potential Celiac Disease?

PURPOSE: Synbiotics can alleviate some intestinal pathologies or prevent trigger mechanisms for some diseases such as celiac disease (CD). If patients with high levels of anti-tissue transglutaminase (anti-tTG) immunoglobulin A (IgA) antibodies have normal duodenal histology, they are followed as po...

Descripción completa

Detalles Bibliográficos
Autor principal: Demiroren, Kaan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354869/
https://www.ncbi.nlm.nih.gov/pubmed/32704500
http://dx.doi.org/10.5223/pghn.2020.23.4.397
_version_ 1783558181913362432
author Demiroren, Kaan
author_facet Demiroren, Kaan
author_sort Demiroren, Kaan
collection PubMed
description PURPOSE: Synbiotics can alleviate some intestinal pathologies or prevent trigger mechanisms for some diseases such as celiac disease (CD). If patients with high levels of anti-tissue transglutaminase (anti-tTG) immunoglobulin A (IgA) antibodies have normal duodenal histology, they are followed as potential CD patients. The aim of this study was to investigate the effect of synbiotic use on the blood levels of anti-tTG antibodies in children. METHODS: Eighty-two patients with high anti-tTG levels were included in this study. Patients were randomly divided into two groups. The synbiotic group was treated with a daily dose of a synbiotic including multi-strain probiotics for 20 days. The control group was not administered any medication. Anti-tTG values at baseline and repeat measurements and the percentage change in anti-tTG levels between groups were compared. RESULTS: The anti-tTG level at baseline was 36 U/mL (interquartile range [IQR], 26.4–68 U/mL) in the synbiotic group, and it decreased significantly to 13 U/mL (IQR, 6.5–27.5 U/mL) after 20 days (p<0.05). The anti-tTG level at baseline was 46 U/mL (IQR, 31–89 U/mL) in the control group, which also decreased significantly to 23 U/mL (IQR, 7–41 U/mL) after 20 days (p<0.05). Anti-tTG levels exhibited 73% and 56% decreases in the synbiotic and control groups, respectively (p<0.05). CONCLUSION: It may be speculated that a synbiotic supplementation can contribute to decreasing anti-tTG levels in children with potential CD.
format Online
Article
Text
id pubmed-7354869
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition
record_format MEDLINE/PubMed
spelling pubmed-73548692020-07-22 Can a Synbiotic Supplementation Contribute to Decreasing Anti-Tissue Transglutaminase Levels in Children with Potential Celiac Disease? Demiroren, Kaan Pediatr Gastroenterol Hepatol Nutr Original Article PURPOSE: Synbiotics can alleviate some intestinal pathologies or prevent trigger mechanisms for some diseases such as celiac disease (CD). If patients with high levels of anti-tissue transglutaminase (anti-tTG) immunoglobulin A (IgA) antibodies have normal duodenal histology, they are followed as potential CD patients. The aim of this study was to investigate the effect of synbiotic use on the blood levels of anti-tTG antibodies in children. METHODS: Eighty-two patients with high anti-tTG levels were included in this study. Patients were randomly divided into two groups. The synbiotic group was treated with a daily dose of a synbiotic including multi-strain probiotics for 20 days. The control group was not administered any medication. Anti-tTG values at baseline and repeat measurements and the percentage change in anti-tTG levels between groups were compared. RESULTS: The anti-tTG level at baseline was 36 U/mL (interquartile range [IQR], 26.4–68 U/mL) in the synbiotic group, and it decreased significantly to 13 U/mL (IQR, 6.5–27.5 U/mL) after 20 days (p<0.05). The anti-tTG level at baseline was 46 U/mL (IQR, 31–89 U/mL) in the control group, which also decreased significantly to 23 U/mL (IQR, 7–41 U/mL) after 20 days (p<0.05). Anti-tTG levels exhibited 73% and 56% decreases in the synbiotic and control groups, respectively (p<0.05). CONCLUSION: It may be speculated that a synbiotic supplementation can contribute to decreasing anti-tTG levels in children with potential CD. The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2020-07 2020-07-03 /pmc/articles/PMC7354869/ /pubmed/32704500 http://dx.doi.org/10.5223/pghn.2020.23.4.397 Text en Copyright © 2020 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition https://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Demiroren, Kaan
Can a Synbiotic Supplementation Contribute to Decreasing Anti-Tissue Transglutaminase Levels in Children with Potential Celiac Disease?
title Can a Synbiotic Supplementation Contribute to Decreasing Anti-Tissue Transglutaminase Levels in Children with Potential Celiac Disease?
title_full Can a Synbiotic Supplementation Contribute to Decreasing Anti-Tissue Transglutaminase Levels in Children with Potential Celiac Disease?
title_fullStr Can a Synbiotic Supplementation Contribute to Decreasing Anti-Tissue Transglutaminase Levels in Children with Potential Celiac Disease?
title_full_unstemmed Can a Synbiotic Supplementation Contribute to Decreasing Anti-Tissue Transglutaminase Levels in Children with Potential Celiac Disease?
title_short Can a Synbiotic Supplementation Contribute to Decreasing Anti-Tissue Transglutaminase Levels in Children with Potential Celiac Disease?
title_sort can a synbiotic supplementation contribute to decreasing anti-tissue transglutaminase levels in children with potential celiac disease?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354869/
https://www.ncbi.nlm.nih.gov/pubmed/32704500
http://dx.doi.org/10.5223/pghn.2020.23.4.397
work_keys_str_mv AT demirorenkaan canasynbioticsupplementationcontributetodecreasingantitissuetransglutaminaselevelsinchildrenwithpotentialceliacdisease